Europe Aptamers Market By Type, By Application, By Technology, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

The Europe Aptamers Market is expected to witness market growth of 17.1% CAGR during the forecast period (2021-2027).

Aptamers appear to be low-immunogenic and low-toxic compounds, owing to the fact that nucleic acids are not frequently recognized as foreign agents by the human immune system. Antibodies, on the other hand, are highly immunogenic, making repeat doses impossible. When administered to monkeys in 1,000-fold higher doses, a VEGF-specific aptamer showed low immunogenicity.

Identifying and producing antibodies for poisons or compounds that do not elicit strong immune responses is difficult, yet aptamers can be produced in sufficient numbers. In addition, aptamers have a high affinity and specificity for ligands that antibodies cannot detect, such as ions or tiny molecules, implying that using aptamers as recognition components in biosensors could significantly expand their applications.

Some of the key trends of the regional market are the expanding number of approvals for existing advanced technologies, the rising prevalence of chronic diseases, and the growing demand for aptamer medicines in the region. Europe all contribute to market expansion. Hence, these factors are anticipated to create lucrative growth opportunities for the players operating in the regional aptamers market during the forecasting period.

The Germany market dominated the Europe Aptamers Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $25.7 million by 2027. The UK market is expected to showcase a CAGR of 16.2% during (2021 - 2027). Additionally, The France market is experiencing a CAGR of 18% during (2021 - 2027).

Based on Type, the market is segmented into DNA Aptamers, XNA Aptamers and RNA Aptamers. Based on Application, the market is segmented into Therapeutics Development, Research & Development, Diagnostic and Others. Based on Technology, the market is segmented into SELEX and Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Kaneka Corporation, Aptamer Group PLC, SomaLogic, Inc., RayBiotech Life, Inc., Neoventures Biotechnology, Inc., Maravai Lifesciences Holdings, Inc., Aptus Biotech, Base Pair Biotechnologies, Inc., Alpha Diagnostic International, Inc., and Vivonics, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Type

• DNA Aptamers
• XNA Aptamers and
• RNA Aptamers

By Application

• Therapeutics Development
• Research & Development
• Diagnostic and
• Others

By Technology

• SELEX and
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Government Research Institutes
• CROs and
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Kaneka Corporation
• Aptamer Group PLC
• SomaLogic, Inc.
• RayBiotech Life, Inc.
• Neoventures Biotechnology, Inc.
• Maravai Lifesciences Holdings, Inc.
• Aptus Biotech
  
• Base Pair Biotechnologies, Inc.
• Alpha Diagnostic International, Inc.
• Vivonics, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free